Cargando…

Studies Recommending Palivizumab Restriction Have Serious Deficiencies

Detalles Bibliográficos
Autor principal:	Stewart, Dan L.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Academy of Managed Care Pharmacy 2010
Materias:	Letters
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10437328/ https://www.ncbi.nlm.nih.gov/pubmed/20726681 http://dx.doi.org/10.18553/jmcp.2010.16.7.509

Ejemplares similares

The Medicaid Cost of Palivizumab
por: Ambrose, Christopher S., et al.
Publicado: (2015)

Respiratory syncytial virus and palivizumab prophylaxis in the COVID-19 era
por: Taylor, Richard S.
Publicado: (2021)

Revised recommendations concerning palivizumab prophylaxis for respiratory syncytial virus (RSV)
por: Bollani, Lina, et al.
Publicado: (2015)

Serious Adverse Events in the Canadian Registry of Children Receiving Palivizumab (CARESS) for Respiratory Syncytial Virus Prevention
por: Chen, Jinghan Jenny, et al.
Publicado: (2015)

Molecular characterization of respiratory syncytial viruses infecting children reported to have received palivizumab immunoprophylaxis
por: Oliveira, Danielle B.L., et al.
Publicado: (2015)

The impact of the recent AAP changes in palivizumab authorization on RSV-induced bronchiolitis severity and incidence
por: Capizzi, Antonino, et al.
Publicado: (2017)

Palivizumab reimbursement criteria and neonatal RSV hospitalisation: a regional retrospective review
por: Belleudi, Valeria, et al.
Publicado: (2021)

Safety and Effectiveness of Palivizumab in Children at High Risk of Serious Disease Due to Respiratory Syncytial Virus Infection: A Systematic Review
por: Wegzyn, Colleen, et al.
Publicado: (2014)

A prospective, open-label, non-comparative study of palivizumab prophylaxis in children at high risk of serious respiratory syncytial virus disease in the Russian Federation
por: Turti, Tatyana V, et al.
Publicado: (2012)

Statistical Power to Detect an Association Between Guideline-based Palivizumab Administration and Hospitalizations for Respiratory Syncytial Virus Infections
por: Ambrose, Christopher S.
Publicado: (2017)

Pulmonary Deposition of Radionucleotide-Labeled Palivizumab: Proof-of-Concept Study
por: Rajapaksa, Anushi E., et al.
Publicado: (2020)

Serious vitamin D deficiency in healthcare workers during the COVID-19 pandemic
por: Funaki, Takanori, et al.
Publicado: (2022)

Development of a palivizumab specialty pharmacy management program
por: Harlan, Lana, et al.
Publicado: (2019)

Is immunization with palivizumab really effective in high-risk children?
por: Raguž, Marjana Jerković, et al.
Publicado: (2023)

Association of RSV-related hospitalization and non-compliance with Palivizumab among commercially insured infants: a retrospective claims analysis
por: Stewart, Dan L, et al.
Publicado: (2013)

A Systematic Review of Compliance with Palivizumab Administration for RSV Immunoprophylaxis
por: Frogel, Michael
Publicado: (2010)

Cost effectiveness of palivizumab in Spain: an analysis using observational data
por: Nuijten, Mark J., et al.
Publicado: (2009)

Neonatal outcomes following new reimbursement limitations on palivizumab in Italy
por: Belleudi, Valeria, et al.
Publicado: (2018)

Reappraisal of the Subtropical Guidelines on Palivizumab Prophylaxis in Congenital Heart Disease
por: Chiu, Shuenn-Nan, et al.
Publicado: (2022)

Impact of the use of immunoglobulin palivizumab in the State of São Paulo: a cohort study
por: Gonçalves, Ivana Regina, et al.
Publicado: (2017)

A post-incorporation study on the use of palivizumab in the Brazilian public health system
por: Batista, Joanna d’Arc Lyra, et al.
Publicado: (2021)

Respiratory Syncytial Virus Immunoprophylaxis with Palivizumab: 12-Year Observational Study of Usage and Outcomes in Canada
por: Mitchell, Ian, et al.
Publicado: (2021)

Respiratory infections in children up to two years of age on prophylaxis with palivizumab
por: Monteiro, Ana Isabel M. P., et al.
Publicado: (2014)

Safety and pharmacokinetics of extended use of palivizumab in Saudi Arabian infants and children
por: al-Alaiyan, Saleh, et al.
Publicado: (2015)

Palivizumab Prophylaxis for Respiratory Syncytial Virus: Examining the Evidence Around Value
por: Olchanski, Natalia, et al.
Publicado: (2018)

Reducing Palivizumab Dose Requirements Through Rational Dose Regimen Design
por: Reuter, Stephanie E., et al.
Publicado: (2018)

Safety, efficacy and pharmacokinetics of palivizumab in off-label neonates, infants, and young children at risk for serious respiratory syncytial virus infection: a multicenter phase II clinical trial
por: Mori, Masaaki, et al.
Publicado: (2023)

Summary of the National Advisory Committee on Immunization (NACI) statement update on the recommended use of palivizumab to reduce complications of respiratory syncytial virus infection in infants
por: Moore, Dorothy, et al.
Publicado: (2022)

Brain cell membrane motion-restricted phospholipids in patients with schizophrenia who have seriously and dangerously violently offended
por: Puri, Basant K, et al.
Publicado: (2010)

Recommendations for the Design of Serious Games in Neurodegenerative Diseases
por: Ben-Sadoun, Grégory, et al.
Publicado: (2018)

Medical Utilization Associated with Palivizumab Compliance in a Commercial and Managed Medicaid Health Plan
por: Diehl, Jocelyn L., et al.
Publicado: (2010)

Utilization Management Opportunities for Palivizumab for Prophylaxis of Respiratory Syncytial Virus Complications in Infants
por: Curtiss, Frederic R., et al.
Publicado: (2010)

Impact of Palivizumab on RSV Hospitalizations for Children with Hemodynamically Significant Congenital Heart Disease
por: Chang, Ruey-Kang R., et al.
Publicado: (2009)

Review of palivizumab in the prophylaxis of respiratory syncytial virus (RSV) in high-risk infants
por: Mejías, Asunción, et al.
Publicado: (2008)

Respiratory Syncytial Virus Infection in High-risk Infants – an Update on Palivizumab Prophylaxis
por: Resch, Bernhard
Publicado: (2014)

Assessing Variation in the Cost of Palivizumab for Respiratory Syncytial Virus Prevention in Preterm Infants
por: Shahabi, Ahva, et al.
Publicado: (2017)

Product review on the monoclonal antibody palivizumab for prevention of respiratory syncytial virus infection
por: Resch, Bernhard
Publicado: (2017)

Human respiratory syncytial virus and other viral infections in infants receiving palivizumab
por: Boivin, Guy, et al.
Publicado: (2008)

Compliance with The RSV Immunoprophylaxis Dosing Schedule in The Polish Registry for Palivizumab (2008-2014)
por: Borecka, Róża, et al.
Publicado: (2019)

Post-translational modifications and glycoprofiling of palivizumab by UHPLC–RPLC/HILIC and mass spectrometry
por: Sran, Kulwinder Singh, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_dadl4n5papqqqlvbohqj3504c8